The GSTT1 deletion polymorphism is associated with initial response to glucocorticoids in childhood acute lymphoblastic leukemia Leukemia (2004) As early as in the 1970s, the Berlin-Frankfurt-Mü nster (BFM) study group started to evaluate the early response to prednisone treatment, the so-called prednisone response, as a prognostic factor for treatment outcome. 1 Prednisone response is characterized by the peripheral blood leukemic blast count on day 8 of treatment initiation after a 7-day monotherapy with prednisone and one intrathecal dose of methotrexate on treatment day 1. Good response is defined through a peripheral blood blast count of o1000/ml, while poor response is characterized by X1000 blasts/ml. As the event-free survival rates between prednisone good and poor responders differ significantly (roughly 80 vs 30-40%), the identification of factors associated with and potentially accounting for these differences is of great clinical interest.
Cytosolic glutathione S-transferases (GST) are dimeric proteins that belong to the group of phase II enzymes and play an important role in the protection against products of oxidative stress and electrophiles. 2 At least seven distinct classes of soluble GSTs have been identified so far: alpha (a), mu (m), pi (p), sigma (s), theta (y), kappa (k), and zeta (z). GSTs detoxify a wide range of xenobiotics as well as endogenous reactive species by either catalyzing the conjugation of reduced glutathione to the substrate or sequestrating toxic compounds. Of interest, GSTs have been suggested to play a role in steroid metabolism/ resistance, as they were shown to bind to steroid hormones including glucocorticoids. 3 In a recent case-control study on four phenotypically relevant GST genetic polymorphisms and prednisone response in childhood ALL, we observed a tendency for patients with the GSTT1 n 0/ 0 genotype to have a better response to prednisone when compared to study subjects with the GSTT1 n A/0 or n A/A genotypes (P ¼ 0.07), while none of the other investigated GST polymorphisms (GSTM1 deletion polymorphism, GSTP1 codon 105 and 114 single-nucleotide polymorphisms) was suggestive of an association. 4 However, the previous approach to GSTT1 genotyping was limited to the detection of presence of one or two alleles vs complete absence of the GSTT1 gene.
5 GSTT1 is homozygously deleted in approximately 10-20% of Caucasians, 25% of African Americans and more than 50% of Asians and correlates with the nonconjugator phenotype of GSTT1. 6, 7 Meanwhile, the GSTT1 deletion polymorphism was characterized at the molecular level, which now allows discrimination of all three GSTT1 genotypes (homozygous presence:
n A/A; heterozygous: n A/0; homozygous deletion:
n 0/0). 8 Thus, in order to confirm our previous findings from a case-control study in a larger cohort study and to more precisely assess the association of GSTT1 genetic variation with the initial response to glucocorticoids in childhood ALL, we genotyped 420 pediatric ALL patients (including 53 prednisone poor responders) consecutively enrolled in our current trial ALL-BFM 2000 for the GSTT1 deletion polymorphism.
The present study used data from the ongoing ALL-BFM 2000 trial that is conducted by the BFM study group and enrolls pediatric patients up to 18 years of age with a diagnosis of ALL from 84 different treatment centers in Germany, Austria, and Switzerland. From July 1999 until the end of February 2001, 497 patients of up to 18 years of age were enrolled onto the clinical trial after informed consent was obtained from the parents or legal guardians. Treatment during the first 7 days in ALL-BFM 2000 consists of a prednisone monotherapy (60 mg/m 2 /day) and one intrathecal application of methotrexate on day 1 (o1 year of age: 6 mg; 1-o2 years: 8 mg; 2-o3 years: 10 mg; X3 years: 12 mg). The first day of treatment was the day of first administration of prednisone. Until bone marrow evaluation on treatment day 15, glucocorticoid therapy was continued and accompanied by one single intravenous injection of vincristine (1.5 mg/m 2 ; max. dose 2 mg) and a 1-h infusion of daunorubicin (30 mg/m 2 ) both on treatment day 8. Patients were included into the present study, when centrally evaluated data on the in vivo prednisone response on day 8 of treatment initiation and biological material were available at the study center. These requirements led to a study population of 420 patients (84.5% of the entire study population) who with regard to clinical characteristics did not significantly differ from the entire study population of 497 patients. DNA was extracted from peripheral blood or bone marrow samples by using the QIAamp DNA Blood Midi Kit (Qiagen GmbH, Hilden, Germany). GSTT1 genotyping was performed according to the polymerase chain reaction assay recently published by Sprenger et al. Table 1 shows the distribution of clinical characteristics in the entire present study sample of 420 childhood ALL patients and stratified by prednisone response (good or poor response). As expected from previous studies, patients with, for example, male gender, an age at diagnosis of X6 years, an initial white blood cell count of X10 000/ml, an initial peripheral leukemic blast count of X3600/ml (Xthe median), and T-ALL or an initial hemoglobin of X8 g/dl (Xthe median) showed significantly more often a poor response to prednisone compared to their counterparts. The GSTT1 genotype frequencies in our study population of 420 patients were in Hardy-Weinberg equilibrium (P ¼ 0.49) and distributed as follows:
n A/0 ¼ 183 (43.6%), and n 0/0 ¼ 62 (14.8%). To increase sample size, genomic DNA was prepared either from tumor or remission samples, depending on the availability of specimen. No differences with regard to GSTT1 genotype distribution were observed between tumor and remission samples (P ¼ 0.75).
When analyzed in the entire study population, there was a nonsignificant tendency towards a better treatment response to prednisone in children with the GSTT1 n 0/0 genotype compared to those with the n A/A genotype (RR ¼ 0.41; 95% CI ¼ 0.14-1.24; P ¼ 0.12) ( Table 2) . No difference was observed Table 1 Clinical characteristics of all patients from ALL-BFM 2000 trial with acute lymphoblastic leukemia and according to in vivo prednisone response All pts., n (%) (total n ¼ 420) n A/0 and n A/A genotypes. As described above, there are several clinical characteristics known to be associated with prednisone response. In order to assess potential confounding, we next analyzed the associations of GSTT1 genotype with any of the clinical characteristics known to be associated with prednisone response and, besides an association with TEL/AML1 fusion transcript status, did not find any significant associations. However, the distribution of GSTT1 genotypes in TEL/AML1-positive patients (n ¼ 88) was not in accordance with a potential etiologically meaningful gene dosage effect, as these patients compared to TEL/AML1 negatives (n ¼ 297) showed a higher percentage of the n A/A genotype, a lower percentage of heterozygotes, and slightly more homozygous deletions (TEL/AML1 positives:
Consequently, further analyses on the association of GSTT1 genotype with prednisone response were performed stratified by those characteristics significantly associated with prednisone response (Table 2 ). In these analyses, patients at higher risk of prednisone poor response constantly showed decreases in risk of prednisone poor response with 'decreasing' GSTT1 gene dose (Table 2 ). For example, in patients with initial blast counts Xthe median of 3600/ml, accounting for 51 (96.2%) of the 53 prednisone poor responders in our study group, logistic regression analysis revealed that patients with the GSTT1 n A/0 genotype showed a 1.4-fold (P ¼ 0.32) and those with the GSTT1 n 0/0 genotype a 4-fold decrease (P ¼ 0.04) in risk of prednisone poor response compared to patients with the GSTT1 n A/A genotype (P for trend of risk reduction over the categories ¼ 0.03). Multivariate analyses did not significantly alter the point estimates.
As prednisone response is defined through a fixed value of 1000 peripheral leukemic blasts/ml at treatment day 8, we introduced more variability and calculated the percentage of peripheral leukemic blast cell reduction after the first week of treatment. Peripheral leukemic blast cell reduction was not normally distributed but severely skewed as approximately 50.0% of patients had blast reductions of X99.0%. While by Mann-Whitney U-test no significant differences were observed in patients with initial blast cell counts othe median of 3600/ml, patients with initial blast cell counts Xthe median of 3600/ml showed higher blast cell reductions when possessing the GSTT1 n A/0 (P ¼ 0.06) or the GSTT1 n 0/0 (P ¼ 0.02) in comparison to patients with the GSTT1 n A/A genotype. Although only 79.0% of patients with initial blast cell counts Xthe median of 3600/ml had this information available, this association was also reflected by median blast percentages in the bone marrow on treatment day 15: GSTT1 n 0/0 ¼ 3.75%; GSTT1 n A/0 ¼ 5.75%; and GSTT1 n A/A ¼ 7.50% (Mann-Whitney U-test: n A/0 compared to n A/A, P ¼ 0.36, n 0/0 compared to n A/A, P ¼ 0.05). Our finding of an association between GSTT1 genotype and the initial response to glucocorticoid treatment in childhood ALL in our present study is consistent with previous findings of our group in patients treated on the BFM protocols ALL-BFM 86 and 90. 4 In addition, our findings on the association of GSTT1 genotype and prednisone response are supported by similar findings when looking at the relative blast count reduction during the first week of treatment and the bone marrow rating for blast cells on treatment day 15. With regard to treatment outcome, the median follow-up of the patient sample investigated in the present study is clearly too short to allow for an analysis of its association with GSTT1 genotype. In conclusion, our results support a modulating effect of the GSTT1 deletion polymorphism on the early response to treatment in childhood ALL treated on BFM protocols and should promote biological studies to better understand the mechanism by which this may happen.
